Serina Therapeutics (SER) said Wednesday it sold its UniverXome subsidiary.
The deal, which was finalized on Dec. 23, cut $11.2 million in associated subsidiary-level debt, Serina said, adding it now has a debt-free balance sheet.
The unit was set up before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold the legacy assets of the predecessor company, Serina said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.